Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults
| Status: | Recruiting |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), Renal Impairment / Chronic Kidney Disease, Hospital, Hospital |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Nephrology / Urology, Other |
| Healthy: | No |
| Age Range: | 18 - 24 |
| Updated: | 2/9/2019 |
| Start Date: | December 2015 |
| End Date: | February 2020 |
| Contact: | Marie-Carmelle Elie, MD |
| Phone: | 352-265-5911 |
Long Term Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults - IMPRESS YA
Sepsis is the most common cause of childhood death worldwide. Millions of children survive,
but are left with impaired health. Sepsis-related Acute Kidney Injury (sAKI) is increasingly
recognized as a significant factor associated with long-term mortality among different
patient populations. Renal dysfunction and subsequent chronic kidney disease is implicated in
the development of hypertension and cardiovascular disease. The investigators overall
hypothesis is that, in the pediatric population, sepsis-related AKI will have unrecognized,
long-term consequences with regard to kidney function, endothelial function, blood pressure
control, and overall health.
but are left with impaired health. Sepsis-related Acute Kidney Injury (sAKI) is increasingly
recognized as a significant factor associated with long-term mortality among different
patient populations. Renal dysfunction and subsequent chronic kidney disease is implicated in
the development of hypertension and cardiovascular disease. The investigators overall
hypothesis is that, in the pediatric population, sepsis-related AKI will have unrecognized,
long-term consequences with regard to kidney function, endothelial function, blood pressure
control, and overall health.
This will be a two-arm cross-sectional control-cohort outpatient evaluation. Subjects with
sAKI and a random selection of non-sAKI subjects who agree to participate in another study of
quality of life survey will be asked to participate in the outpatient study. Subjects will be
asked to come in to the Clinical Research Center for 24-hour monitoring and participate in
the outpatient study where urinary and serum studies to measure glomerular filtration rate,
renal plasma flow followed by blood pressure monitoring, peripheral arterial and applanation
tonometry.
sAKI and a random selection of non-sAKI subjects who agree to participate in another study of
quality of life survey will be asked to participate in the outpatient study. Subjects will be
asked to come in to the Clinical Research Center for 24-hour monitoring and participate in
the outpatient study where urinary and serum studies to measure glomerular filtration rate,
renal plasma flow followed by blood pressure monitoring, peripheral arterial and applanation
tonometry.
Inclusion Criteria:
For all patients:
• Age 18-24 at time of participation in the study
For non-AKI sepsis patients:
- Hospitalization with a diagnosis of sepsis from 1998-2014
- Failure to meet pEDRIFLE criteria for AKI during incident sepsis admission
- Participation in cognitive survey study with completion of the PedsQL survey
For sAKI patients:
- Hospitalization with a diagnosis of sepsis from 1998-2014
- Severe AKI as defined by the pEDRIFLE criteria during incident sepsis admission
- Participation in cognitive survey study with completion of the PedsQL survey
Exclusion Criteria:
For all patients:
- Known pre-existing CKD as defined by history of kidney transplant or long-term
dialysis
- Age greater than 18 years at the time of incident sepsis admission
- AKI from primary kidney disease including acute glomerulonephritis and obstructive
uropathy
- Pregnancy at the time of enrollment
- Known or suspected allergy to gadolinium based contrast
- Known or suspected allergy to iodine or shellfish will be excluded from RPF
measurement with iodohippurate
- Heart failure or condition whereby the administration of 0.9% normal saline would be
contraindicated
We found this trial at
1
site
Gainesville, Florida 32608
Principal Investigator: Marie-Carmelle Elie, MD
Phone: 352-265-5911
Click here to add this to my saved trials
